The estimated inclusion period is 45 months. Patient follow-up is 24 months and the total study duration is 69 months. Last patient status (alive or dead) collected before database lock.
Primary Objective:~-Evaluate the resection rate (R0/R1) in current practice for aflibercept in combination with irinotecan plus 5-fluorouracil (FOLFIRI) in patients treated for metastatic colorectal cancer (mCRC) after failure of an oxaliplatin-containing regimen~Secondary Objectives:~Evaluate overall survival, progression-free survival and relapse-free survival.~Evaluate conversion rates (initially unresectable disease which became resectable after chemotherapy, with R0/R1 resection).~Evaluate histological and radiological response rates.~Evaluate rate of postoperative complications.~Evaluate safety.